Overview
- The company will lease 250,000 square feet at the former refinery site to manufacture actinium-225 for targeted alpha therapies.
- Pennsylvania committed $10 million in grants, and the Keystone Opportunity Zone status provides tax advantages through 2043.
- Officials project about 225 full-time jobs in Philadelphia over the next three years, with no construction timeline announced.
- TerraPower Isotopes selected Philadelphia from more than 350 candidate locations, citing proximity to the region's life-sciences ecosystem.
- Global output of actinium-225 remains extremely limited, described by Canadian Nuclear Laboratories as less than a grain of sand annually.